BACKGROUND Patients with left bundle branch block (LBBB) often respond to cardiac resynchronization therapy
Most clinical trials that have studied CRT have found that it is only efficacious in patients with left bundle branch block (LBBB) (5, (9) (10) (11) (12) . This implicitly suggests that LBBB may represent a previously unrecognized cause of LV dysfunction. Although LBBB has long been identified as a comorbid factor carrying an adverse prognosis, there is now evidence that LBBB not only leads to adverse patient outcomes in otherwise healthy patients, but as seen in dog models, and small retrospective series, may also be a potential cause of nonischemic cardiomyopathy itself (13) (14) (15) (16) (17) .
Although CRT is considered the definitive treatment for patients with LBBB and symptomatic cardiomyopathy, it remains unclear how LBBB affects rates of LV functional recovery in patients without a cardiac device. For example, current guidelines recommend at least 3 months of guideline-directed medical therapy (GDMT) before implantation of CRT, in the hopes that medical therapy alone will lead to improvement in LVEF (8) . However, it is worth emphasizing that none of the major trials supporting medical therapy stratified outcome analyses by the presence or absence of LBBB or reported QRS morphology as a baseline clinical characteristic (18) (19) (20) (21) (22) (23) (24) (25) .
This study sought to examine how LBBB affects rates of LV functional recovery in patients with cardiomyopathy. We made use of the Duke Echocardiography Laboratory Database and Duke Electrocardiography database to identify patients with a diagnosis of cardiomyopathy, an electrocardiogram (ECG), and a follow-up echocardiogram in 3 to 6 months. We hypothesized that in the "real world," LBBB would be a significant predictor for decreased rates of LV functional recovery, and that many patients with LBBB would not improve their LVEF by >35%. This would suggest that some patients might benefit from receiving CRT earlier than current guidelines recommend.
METHODS
DATA SOURCES. The study cohort was selected from the Duke Echocardiography Laboratory Database. It includes all clinical echocardiograms performed at Duke University Health System since 1995, and its setup has been described previously (26) Intercurrent myocardial infarction was pre-specified to be any myocardial infarction that occurred between baseline and follow-up echocardiogram.
Heart failure hospitalizations after follow-up echocardiogram could be obtained for any admission at a Duke-affiliated hospital through the electronic medical record. All-cause mortality was obtained through the medical record and National Death Index. Patients without a clinical read of LBBB were stratified by QRS duration. Patients without LBBB who had a wide QRS duration $120 ms (WQRS) were placed into one group, whereas patients with a narrow QRS duration <120 ms (NQRS) were placed into a second comparator group. For the purpose of a sensitivity analysis, a physician trained in the Strauss criteria provided an additional over-read of all LBBB ECGs and placed these patients either into a strict LBBB group or back into the WQRS group (27) . Use of GDMT was defined as use of a beta-blocker (BB) plus an and p values for a significant change in LVEF overtime.
Multiple comparison procedures using Tukey's adjustment were conducted to determine specific group differences in adjusted mean LVEF change (29) .
A second analysis conducted unadjusted and adjusted binary logistic regression analyses to deter- 
RESULTS
The study population consort diagram is presented in Figure 1 . Fewer NQRS patients died before potential
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follow-up echocardiogram. More LBBB patients were excluded for receiving a cardiac device, left ventricular assist device, or heart transplant. Baseline clinical characteristics are presented in baseline heart failure. Patients with NQRS also had a higher percentage of patients with baseline heart rates >120 beats/min, though this difference was not statistically significant. All 3 groups were prescribed similar rates of BBs, ACE inhibitors, ARBs, and aldosterone antagonists. Medications at baseline and follow-up are presented in Online Table 1 and show remarkable similarity in mean dose and use rates.
More LBBB and WQRS patients used ARBs at baseline, though use rates were low (between 7% and 14%).
Roughly two-thirds of patients in each group were on GDMT (76 of 111 patients [69%] for LBBB; 39 of 59 for NQRS). There were no significant differences in valvular heart disease among the 3 groups. Table 3 shows analysis of variance results from changes in LVEF over time.
When adjusted for pre-specified comorbidities and significant differences in baseline characteristics, the mean changes in LVEF were 2.03%, 5.28%, and 8.00%
for LBBB, WQRS, and NQRS, respectively. Differences between LBBB and NQRS were highly significant (p < 0.0001), though not significant between LBBB and WQRS.
At follow-up, 23% of patients with LBBB improved their LVEF to >35%, compared with 27% with WQRS, and 43% with NQRS. On the whole, patients with LBBB were more likely to stay the same or worsen their LVEF on follow-up and the least likely to improve their LVEF >35% ( Table 2 ).
The Central Illustration shows mean plots for LVEF change between the 3 groups for baseline and followup echo. Figure 2 shows Kaplan-Meier curves for time to heart failure hospitalization, all-cause mortality, and heart failure hospitalization or all-cause mortality. Patients with LBBB were significantly more likely Values are mean AE SD, n (%), median (interquartile range), or n.
Abbreviations as in Table 1 . to experience a heart failure event and a combined endpoint of heart failure hospitalization or mortality.
Median follow-up was 4.3 years. Online Tables 2 and 3 Table 2 ). The results were also very similar when analyses were rerun with a strict LBBB group (Online Table 3 ).
DISCUSSION
This study shows that patients with a baseline LVEF #35% and LBBB demonstrate significantly less LV functional recovery than those with NQRS, even after 3 to 6 months of medical therapy. Death Index. HF hospitalization data were acquired through the medical record at Duke-affiliated hospitals. Because all echocardiograms were performed before 2015, events were censored at December 31, 2014, matching the end date of the National Death Index query. All curves were censored at 10 years post-follow-up echocardiography. KM ¼ Kaplan-Meier; other abbreviations as in Figure 1 .
Oral Carvedilol Heart Failure Assessment) trial
showed that carvedilol could improve EF by 5% to 8% over a 6-month period ( *Adjusted for baseline LVEF, GDMT, history of atrial fibrillation/flutter, age, sex, history of cerebrovascular disease, prior MI, baseline heart rate on ECG, history and duration of heart failure, and left atrium size; 1 patient excluded due to missing HR.
OR ¼ odds ratio; other abbreviations as in Tables 1 and 3 . An earlier meta-analysis of 5 randomized trials also showed QRS duration of 160 ms to be most predictive of CRT response (42 We also did not have data on NYHA functional class, which might have identified important differences in our study population. Data for heart failure hospitalization were also limited to those patients admitted to a Duke-affiliated hospital. Last, study enrollment required patients to have a follow-up
echocardiogram. This might have created selection EF ¼ ejection fraction; other abbreviations as in Table 1 . bias. However, the study consort diagram shows higher rates of patients with LBBB excluded due to need for a cardiac device, left ventricular assist device, or transplant, whereas exclusions due to mortality were less for the NQRS group. This is in line with extensive data that suggest that LBBB aggravates cardiomyopathy and leads to worse outcomes (5, 9, 44 
